Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Svetlana, Dimova"'
Autor:
Hina Dave, Jacqueline A. French, Heidi Henninger, Hamada Hamid Altalib, Roger Porter, Michael Gelfand, Melinda S. Martin, Prashant Dongre, Sami Elmoufti, Anne-Liv Schulz, Svetlana Dimova, Michael R. Sperling
Publikováno v:
Thursday, April 27.
Autor:
Philippe Ryvlin, Svetlana Dimova, Sami Elmoufti, Florin Floricel, Cédric Laloyaux, Xavier Nondonfaz, Victor Biton
Publikováno v:
Ryvlin, P, Dimova, S, Elmoufti, S, Floricel, F, Laloyaux, C, Nondonfaz, X & Biton, V 2022, ' Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use : Pooled results from three phase 3 trials ', Epilepsia, vol. 63, no. 8, pp. 2024-2036 . https://doi.org/10.1111/epi.17304
Objective: This study was undertaken to evaluate safety/tolerability and efficacy of adjunctive brivaracetam (BRV) in patients on one or two concomitant antiseizure medications (ASMs) and in patients on one specific concomitant ASM. Methods: Post hoc
Autor:
Christian, Brandt, Svetlana, Dimova, Sami, Elmoufti, Cédric, Laloyaux, Xavier, Nondonfaz, Pavel, Klein
Publikováno v:
Epilepsy & Behavior. 138:108967
To evaluate long-term retention, reasons for discontinuation, efficacy, tolerability, and health-related quality of life (HRQOL) during adjunctive brivaracetam (BRV) treatment in adults with focal seizures by number of lifetime antiseizure medication
Autor:
Tony Daniels, Paul Martin, Ying Zhang, Nancy Yuen, Simon Borghs, Svetlana Dimova, Barbara Steinborn, Hannah C. Carney, Ali Bozorg, Viktor Farkas, Ingrid E. Scheffer, J. Robert Flamini
Publikováno v:
Neurology
ObjectiveTo evaluate efficacy and tolerability of adjunctive lacosamide in children and adolescents with uncontrolled focal (partial-onset) seizures.MethodsIn this double-blind trial (SP0969;NCT01921205), patients (age ≥4–ResultsThree hundred for
Autor:
Svetlana Dimova, Ying Zhang, Marc De Backer, Scott Mintzer, Björn Steiniger-Brach, Robert Roebling, Daya Chellun
Publikováno v:
Epilepsia. 61(12)
Objective The effects of anticonvulsants on lipids are the subject of considerable concern and investigation, but there are almost no data on this issue from randomized trials. We evaluated serum lipid profiles in adults with newly diagnosed epilepsy
Autor:
Pavel Klein, Sami Elmoufti, Xavier Nondonfaz, Richard S. McLachlan, Kathy Foris, Svetlana Dimova, Christian Brandt
Publikováno v:
Epilepsy research. 167
Objective To evaluate the efficacy and tolerability of adjunctive brivaracetam (BRV) in adults with focal seizures by the number of lifetime (previous and concomitant) antiepileptic drugs (AEDs). Methods Post-hoc analysis of data from N01358 (NCT0126
Publikováno v:
Epilepsy Research. 176:106694
This post hoc analysis was conducted to evaluate the efficacy, tolerability, and health-related quality of life during long-term adjunctive brivaracetam (BRV) treatment in adult patients with focal to bilateral tonic-clonic seizures (FBTCS). Patients
Autor:
Björn Steiniger-Brach, Bruno Ferrò, Reetta Kälviäinen, Ali Bozorg, Christian Brandt, Felix Rosenow, Svetlana Dimova, Ying Zhang, Gregory L. Holmes
Publikováno v:
Acta neurologica ScandinavicaREFERENCES. 141(6)
Objectives To assess tolerability and efficacy of lacosamide in adults with cerebrovascular epilepsy etiology (CVEE). Materials and methods Exploratory post hoc analyses of a double-blind, initial monotherapy trial of lacosamide vs carbamazepine-cont
Publikováno v:
Epilepsy Research. 159:106220
Psychiatric comorbidities are common in patients with epilepsy. A double-blind noninferiority monotherapy trial (SP0993; NCT01243177) enrolled newly diagnosed patients (≥16 years) with focal or generalized tonic-clonic seizures. Patients were rando
Publikováno v:
Annals of the New York Academy of Sciences. 1329:18-32
Lacosamide (LCM) is a functionalized amino acid specifically developed for use as an antiepileptic drug (AED) and is currently indicated as adjunctive treatment for partial-onset seizures in adults with focal epilepsy (maximum approved dose 400 mg/da